IO Biotech, a clinical-stage biopharma company developing immune modulating anti-cancer therapies, has entered into a collaborative agreement with Merck focused on the clinical evaluation of IO102 with KEYTRUDA (pembrolizumab) in non-small cell lung cancer (NSCLC).   IO Biotech’s lead candidate, IO102, is an IDO-derived immune modulating therapy with dual mode of action killing both cancer and immune-suppressive cells. The company’s immune modulating therapies have previously show...